Cancer Immunotherapies, Oncolytic Viruses

Lokon Pharma is at the forefront of developing innovative cancer immunotherapeutics, particularly through its LOAd therapy, which utilizes tumor microenvironment (TME) gene engineering vectors. These vectors are designed to deliver immunostimulatory genes that enhance the immune response against various cancers, including pancreatic, biliary, ovarian, colorectal cancers, and malignant melanoma. The company is currently conducting several Phase I/II clinical trials, such as LOKON001 and LOKON003, to evaluate the efficacy of these therapies in combination with existing treatments like chemotherapy and checkpoint blockade antibodies.

The LOAd family of therapies is characterized by its focus on understanding the mechanisms of action (MOA) and establishing proof-of-concept (POC) for its gene engineering vectors. Lokon Pharma's approach combines solid expertise in cancer biology and immunology with a commitment to addressing high unmet medical needs in oncology. Their ongoing collaborations with other biotech and pharmaceutical companies further enhance their research capabilities and therapeutic offerings, aiming to develop groundbreaking treatments that could significantly improve patient outcomes in cancer care.

Sweden

LOKON PHARMA is a Swedish biotech company in the forefront of developing immunostimulatory gene therapy for cancer-based on oncolytic viruses. Innovative gene engineering, solid expertise in cancer biology and immunology, as well as a genuine curiosity in life science expand Lokon’s pipeline towards groundbreaking new therapeutics for patients with high unmet medical need.

Lokon Pharma

Company Details